AMRN Amarin Corporation plc Stock Quote

AMRN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.05	Insider Own	1.00%	Shs Outstand	390.73M	Perf Week	-16.60%
Market Cap	2.42B	Forward P/E	49.02	EPS next Y	0.12	Insider Trans	-22.76%	Shs Float	376.50M	Perf Month	-19.60%
Income	-18.00M	PEG	-	EPS next Q	-0.06	Inst Own	39.70%	Short Float	5.35%	Perf Quarter	31.09%
Sales	614.10M	P/S	3.94	EPS this Y	28.70%	Inst Trans	0.29%	Short Ratio	2.49	Perf Half Y	-18.07%
Book/sh	1.61	P/B	3.75	EPS next Y	230.00%	ROA	-1.90%	Target Price	10.55	Perf Year	-62.55%
Cash/sh	1.25	P/C	4.83	EPS next 5Y	38.90%	ROE	-3.00%	52W Range	3.36 - 16.47	Perf YTD	23.31%
Dividend	-	P/FCF	-	EPS past 5Y	43.60%	ROI	-3.30%	52W High	-63.75%	Beta	2.34
Dividend %	-	Quick Ratio	2.20	Sales past 5Y	49.70%	Gross Margin	78.60%	52W Low	77.68%	ATR	0.51
Employees	1000	Current Ratio	2.90	Sales Q/Q	16.70%	Oper. Margin	-3.20%	RSI (14)	30.43	Volatility	7.38% 6.85%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-35.90%	Profit Margin	-2.90%	Rel Volume	0.75	Prev Close	6.03
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 25 BMO	Payout	-	Avg Volume	8.08M	Price	5.97
Recom	2.20	SMA20	-21.80%	SMA50	-9.62%	SMA200	-0.13%	Volume	2,498,284	Change	-1.00%

Sep-29-20

Resumed

JP Morgan

Neutral

Aug-26-20

Initiated

Piper Sandler

Overweight

$21

May-05-20

Initiated

Northland Capital

Outperform

$15

Mar-31-20

Upgrade

Oppenheimer

Underperform → Perform

Mar-31-20

Downgrade

Jefferies

Buy → Hold

$30 → $4

Mar-31-20

Downgrade

Goldman

Buy → Neutral

Mar-13-20

Upgrade

Goldman

Neutral → Buy

$28

Mar-02-20

Initiated

Cowen

Outperform

$23

Feb-18-20

Upgrade

Citigroup

Neutral → Buy

$27 → $24

Jan-06-20

Initiated

JP Morgan

Neutral

$22

Dec-16-19

Downgrade

Stifel

Buy → Hold

Nov-20-19

Initiated

Oppenheimer

Underperform

Nov-18-19

Downgrade

Citigroup

Buy → Neutral

Nov-15-19

Reiterated

SVB Leerink

Outperform

$26 → $29

Oct-31-19

Initiated

Aegis Capital

Buy

$23

Oct-15-19

Initiated

Goldman

Neutral

$17

Aug-14-19

Initiated

SVB Leerink

Outperform

$26

Jul-09-19

Reiterated

Jefferies

Buy

$30

Jun-17-19

Initiated

ROTH Capital

Buy

$31

Mar-22-19

Initiated

Stifel

Buy

$27

Mar-01-21 08:00AM	Amarin (AMRN) Q4 2020 Earnings Call Transcript Motley Fool -8.16%
Feb-26-21 09:47AM	Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid Zacks
Feb-25-21 11:21AM	How Amarin Beat Wall Street's Q4 Estimates Motley Fool
05:55AM	Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
Feb-18-21 06:05AM	Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire
Feb-17-21 08:05AM	Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021 GlobeNewswire
Feb-09-21 07:00PM	Why Amarin Rose as Much as 7.9% Today Motley Fool
07:00AM	Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong GlobeNewswire
Feb-07-21 11:27PM	Rock star Growth Puts Amarin (NASDAQ:AMRN) In A Position To Use Debt Simply Wall St.
Feb-01-21 06:25PM	Why Amarin Corporation Shot 7.7% Higher Today Motley Fool +7.73%
Jan-29-21 12:52PM	Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction GlobeNewswire
Jan-26-21 08:07AM	The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga
Jan-25-21 07:35PM	Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider GlobeNewswire +15.42%
Jan-24-21 06:08AM	3 Stocks Wall Street Thinks Will Soar 50% or More in 2021 Motley Fool
Jan-22-21 07:22AM	The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga
Jan-21-21 04:30PM	Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases GlobeNewswire
Jan-09-21 01:36AM	Amarin Corporation plc's (NASDAQ:AMRN) About To Shift From Loss To Profit Simply Wall St.
Jan-07-21 06:05AM	Amarin Provides Preliminary 2020 Results and 2021 Outlook GlobeNewswire +9.69%
Jan-05-21 09:32AM	This Stock Could Be a Surprise Growth Pick for 2021 Motley Fool
Jan-04-21 06:05AM	Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-20 08:46AM	Amarin (AMRN) Surges: Stock Moves 9% Higher Zacks -6.50%
Dec-21-20 09:41AM	Is AMRN A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-14-20 05:00AM	Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results GlobeNewswire
Dec-12-20 09:30PM	Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020 GlobeNewswire
Dec-11-20 10:01AM	Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Zacks
Dec-07-20 07:00AM	VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020 GlobeNewswire
Dec-06-20 11:41PM	The Amarin (NASDAQ:AMRN) Share Price Is Up 168% And Shareholders Are Boasting About It Simply Wall St.
Dec-01-20 08:08AM	The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga
Nov-30-20 07:55PM	Amarin Files Patent Infringement Lawsuit Against Hikma GlobeNewswire +7.83%
Nov-24-20 06:05AM	Amarin to Present at Piper Sandlers 32nd Annual Healthcare Conference (Virtual) GlobeNewswire
Nov-22-20 06:28AM	Amarin vs. the Generics: Who Will Win? Motley Fool
Nov-20-20 10:20AM	ROCE Insights For Amarin Corp Benzinga
10:06AM	Amarin Jumps on Heart-Drug Progress in China Trial TheStreet.com
07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga
Nov-19-20 06:30PM	Amarin Shares Topline Data from Partners Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China GlobeNewswire
Nov-18-20 07:00AM	Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Associations Virtual Scientific Sessions 2020 GlobeNewswire
Nov-13-20 10:00AM	VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Associations Virtual Scientific Sessions 2020 GlobeNewswire +5.94%
Nov-11-20 04:30PM	Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences GlobeNewswire
Nov-09-20 06:58PM	Good Entry Point for Amarin Stock? Not Just Yet, Says Analyst TipRanks
Nov-06-20 10:39AM	Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down Zacks -5.10%
Nov-05-20 09:01PM	Amarin (AMRN) Q3 2020 Earnings Call Transcript Motley Fool -9.62%
09:12AM	Looking Into Amarin Corp's Return On Capital Employed Benzinga
08:54AM	Amarin Corp: Q3 Earnings Insights Benzinga
06:00AM	Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
05:30AM	Are Institutions Heavily Invested In Amarin Corporation plc's (NASDAQ:AMRN) Shares? Simply Wall St.
Oct-29-20 07:00AM	New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Associations Virtual Scientific Sessions 2020 GlobeNewswire
Oct-26-20 05:00PM	Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study Motley Fool
07:00AM	VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Society of Nephrology (ASN) Kidney Week 2020 GlobeNewswire
Oct-23-20 07:00AM	U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride (TG) Levels Despite Well-Controlled Low-Density Lipoprotein (LDL)-Cholesterol GlobeNewswire
Oct-19-20 07:00AM	Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 GlobeNewswire
Oct-16-20 09:50AM	Looking Into Amarin Corp's Return On Capital Employed Benzinga
07:15AM	The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs Benzinga
01:52AM	Amarin Pops 4% After-Hours On Positive PCI Data For Vascepa SmarterAnalyst
Oct-15-20 05:19PM	10 Stocks Moving In Thursday's After-Hours Session Benzinga
04:30PM	VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT) Connect 2020 GlobeNewswire
Oct-13-20 07:11AM	The Top 2 Contrarian Stocks to Buy Right Now Motley Fool
Oct-09-20 08:48AM	Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock? Zacks
Oct-06-20 10:19AM	Unusual Options Activity Insight: Amarin Corp Benzinga
Oct-05-20 09:51AM	ROCE Insights For Amarin Corp Benzinga +13.20%
07:00AM	Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020 GlobeNewswire
Sep-29-20 06:34PM	Amarin Stock at $12 a Share? This Analyst Thinks Its Possible TipRanks
Sep-14-20 11:36PM	Hedge Funds Are Dumping Amarin Corporation plc (AMRN) Insider Monkey
Sep-11-20 08:16PM	Amarin (AMRN): Vascepas International Opportunity Remains Intact, Says Analyst TipRanks
Sep-09-20 07:00AM	Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-04-20 10:45AM	Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips Zacks -5.70%
09:36AM	Amarin Shares Sink As Generic Competition for Fish Oil Heart Drug Looks More Certain Barrons.com
Sep-03-20 04:29PM	Amarin (AMRN) Bears the Brunt of a Price Target Cut TipRanks -9.52%
02:46PM	Appeals Court Rules Against Amarin in Vascepa Patent Dispute Motley Fool
12:00PM	Amarin Loses Appeal in Heart-Treatment Patent Case TheStreet.com
10:51AM	Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation GlobeNewswire
09:58AM	Return On Capital Employed Overview: Amarin Corp Benzinga
Sep-02-20 06:34PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm Newsfile -30.58%
04:21PM	Why Amarin Stock Is Getting Slammed Today Motley Fool
03:15PM	Amarin Shares Off - Analysts Mull Prospects for Patent-Case Appeal TheStreet.com
12:22PM	Amarin Plummets After Patent Appeal Shows Key Drug Sales at Risk Bloomberg
07:25AM	The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO Benzinga
Sep-01-20 04:30PM	Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology GlobeNewswire -6.44%
11:34AM	Amarin Patent Appeal Is a Coin Toss With Billions on the Line Bloomberg
08:22AM	Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock? Zacks
Aug-31-20 10:23PM	Can Amarin Win Its Vascepa Appeal Case? Analyst Weighs In TipRanks +5.43%
Aug-30-20 08:24AM	The Week Ahead In Biotech: Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing Benzinga
Aug-29-20 03:13AM	VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020 GlobeNewswire
Aug-27-20 08:42AM	Amarin (AMRN) in Focus: Stock Moves 5.5% Higher Zacks +8.37%
Aug-26-20 09:42AM	Benzinga's Top Upgrades, Downgrades For August 26, 2020 Benzinga +5.54%
Aug-17-20 07:00AM	Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology GlobeNewswire
Aug-09-20 04:42AM	Amarins Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease SmarterAnalyst
Aug-07-20 12:12PM	Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections GlobeNewswire
Aug-05-20 08:19PM	Amarin: Improving HCP Access Should Drive More Vascepa Sales, Says Analyst TipRanks
11:42AM	Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe Zacks
06:23AM	4 Reasons Amarin Stock Could Tumble Even Further Motley Fool
Aug-04-20 10:01PM	Amarin (AMRN) Q2 2020 Earnings Call Transcript Motley Fool
02:10PM	Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward Benzinga
11:16AM	Amarin's Vascepa Sales Jump 34% in Q2 Despite COVID-19 Headwinds Motley Fool
10:38AM	Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire
07:20AM	Recap: Amarin Q2 Earnings Benzinga
06:30AM	Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire
06:00AM	Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire
Jul-27-20 07:00AM	VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention GlobeNewswire
Jul-23-20 05:54AM	Edited Transcript of AMRN.OQ earnings conference call or presentation 13-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
Jul-21-20 04:15PM	Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 GlobeNewswire

Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ketchum Steven B	Chief Scientific Officer	Feb 01	Option Exercise	2.53	192,358	485,882	600,724	Feb 03 08:02 PM
Ketchum Steven B	Chief Scientific Officer	Feb 01	Sale	8.06	217,728	1,754,134	382,996	Feb 03 08:02 PM
Ketchum Steven B	Chief Scientific Officer	Jan 27	Option Exercise	2.75	278,237	764,566	809,741	Jan 29 08:03 PM
Ketchum Steven B	Chief Scientific Officer	Jan 27	Sale	8.01	421,629	3,378,131	388,112	Jan 29 08:03 PM
STACK DAVID M	Director	Nov 30	Buy	4.86	25,000	121,518	25,000	Dec 02 08:05 PM
THERO JOHN F	President and CEO	Nov 11	Sale	4.07	413,565	1,681,183	2,739,000	Nov 12 08:01 PM
THERO JOHN F	President and CEO	Nov 10	Option Exercise	3.40	615,261	2,091,887	3,306,405	Nov 12 08:01 PM
THERO JOHN F	President and CEO	Nov 10	Sale	4.13	153,840	635,975	3,152,565	Nov 12 08:01 PM
THERO JOHN F	President and CEO	Nov 09	Option Exercise	3.40	134,739	458,113	2,691,144	Nov 12 08:01 PM
Zakrzewski Joseph S	Director	Oct 21	Option Exercise	3.40	100,000	340,000	184,547	Oct 22 08:03 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience